OCTAPHARMA

The report covers idiopathic inflammatory myositis epidemiology, market trends, and emerging drugs in the US, EU4, UK, and Japan. Key highlights include 191,589 diagnosed cases in 2023, expected to rise by 2034, with the US having the highest cases (91,734). Marketed drugs like OCTAGAM 10% and VENOGLOBULIN-IH 5% IV, and emerging therapies such as Dazukibart and Efgartigimod are discussed. The market size was $447M in 2023, projected to grow due to emerging therapies.

The 'Idiopathic Inflammatory Myositis - Market Insights, Epidemiology, and Forecast to 2034' report by ResearchAndMarkets.com provides an in-depth analysis of the market, epidemiology, and emerging therapies for idiopathic inflammatory myositis. Key highlights include the projected growth of the market driven by innovative therapies like dazukibart and efgartigimod, the rising prevalence of cases, and the market size of approximately USD 447 million in 2023, expected to grow at a CAGR of 21.1% by 2034. The report also covers current treatment practices, unmet medical needs, and market share by therapies in the 7MM (US, EU4, UK, Japan).

The immunoglobulin market, valued at US$ 13.36 billion in 2023, is projected to reach US$ 28.70 billion by 2034, driven by its use in treating immunodeficiency and other applications. Key growth factors include immunodeficiency disorders, infections, and thrombocytopenia. North America leads with a 46% share, while Asia-Pacific is expected to grow fastest due to increased health spending and prevalence of autoimmune diseases. Recent advancements include subcutaneous injection therapies and acquisitions by major pharmaceutical companies.